S Chandrasekara, E M Lau, J Anderson, N Collins, R Cordina, C Corrigan, N Dwyer, J Feenstra, M Horrigan, A Keogh, E Kotlyar, M Lavender, T McWilliams, B Rhodes, P Steele, G Strange, V Thakkar, R Weintraub, H Whitford, K Whyte, T Williams, J Wrobel, D T Keating
BACKGROUND: Pulmonary arterial hypertension (PAH) has a progressive, unremitting clinical course. Vasoreactivity testing (VdT) during right heart catheterisation (RHC) identifies a subgroup with excellent long-term response to calcium channel blockade (CCB). Reporting on these patients is limited. Established in 2011, the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry offers the opportunity to assess the frequency of VdT during RHC, treatment and follow up of PAH patients...
December 8, 2022: Heart, Lung & Circulation